Publications by authors named "Michael B Lauritzen"
Objective: This clinical trial investigated the safety and efficacy of single-cycle pembrolizumab in patients with localized deficient mismatch repair (dMMR) colon cancer.
Background: Neoadjuvant immunotherapy has induced remarkable rates of pathological complete response in patients with dMMR colon cancer. However, the optimal length and type of treatment are yet to be determined.
Aim: Bowel dysfunction after colon cancer (CC) surgery is widely neglected in current follow up programmes. This study explored changes in bowel function and quality of life (QoL) from three (3 m) to twelve months (12 m) after surgery in CC patients undergoing right- or left-sided colon resection (RightSCR/LeftSCR) and investigated differences between the two groups 12 m after surgery.
Method: CC patients undergoing surgical resection in 2018-2020 at five surgical departments were included in this population-based prospective cohort study.
Background: Bowel dysfunction following treatment of pelvic organ cancer is prevalent and impacts the quality of life (QoL). The present study aimed to evaluate the feasibility and effects of treating bowel dysfunction in two nurse-led late sequelae clinics.
Material And Methods: Treatment effects were monitored prospectively by patient-reported outcome measures collected at baseline and discharge.
Article Synopsis
- Many people who survive colon cancer experience problems with their bowel function after treatment, like diarrhea and constipation.
- A study in Denmark surveyed colon cancer survivors about how food affects their bowel issues and if they received dietary advice.
- The results showed that about one-third of survivors thought certain foods, especially fatty foods and spices, made their bowel problems worse, but not many remembered getting dietary advice from doctors.
Aim: The aim of this study was to test the feasibility of a new method for systematic screening for late sequelae (LS) following colorectal cancer treatment.
Method: Patients with colorectal cancer from five Danish hospitals were invited to complete a survey about LS at 3, 12, 24 and 36 months after surgery as part of their follow-up. The survey consisted primarily of validated tools, supplemented by a few ad hoc items, measuring bowel, urinary and sexual dysfunction, pain and quality of life and an additional question regarding request for contact.
A 77 year-old male presented a locally advanced small cell anal cancer and simultaneous hepatic and glandular deposits. Due to metastatic disease, chemotherapy with carboplatin and etoposide was the primary choice of treatment. Small cell cancer of the gastrointestinal tract exerts an aggressive clinical course with early metastases and a very poor prognosis.
View Article and Find Full Text PDF